177 related articles for article (PubMed ID: 19884006)
21. Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.
Moravcová D; Krystof V; Havlícek L; Moravec J; Lenobel R; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2989-92. PubMed ID: 12941318
[TBL] [Abstract][Full Text] [Related]
22. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
24. Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
Lyne PD; Aquila B; Cook DJ; Dakin LA; Ezhuthachan J; Ioannidis S; Pontz T; Su M; Ye Q; Zheng X; Block MH; Cowen S; Deegan TL; Lee JW; Scott DA; Custeau D; Drew L; Poondru S; Shen M; Wu A
Bioorg Med Chem Lett; 2009 Feb; 19(3):1026-9. PubMed ID: 19097792
[TBL] [Abstract][Full Text] [Related]
25. B-Raf kinase inhibitors for cancer treatment.
Li N; Batt D; Warmuth M
Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
[TBL] [Abstract][Full Text] [Related]
26. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
[TBL] [Abstract][Full Text] [Related]
27. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
28. Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9.
Phillipson LJ; Segal DH; Nero TL; Parker MW; Wan SS; de Silva M; Guthridge MA; Wei AH; Burns CJ
Bioorg Med Chem; 2015 Oct; 23(19):6280-96. PubMed ID: 26349627
[TBL] [Abstract][Full Text] [Related]
29. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
[TBL] [Abstract][Full Text] [Related]
30. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
[TBL] [Abstract][Full Text] [Related]
31. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
[TBL] [Abstract][Full Text] [Related]
32. Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.
Kopecky DJ; Hao X; Chen Y; Fu J; Jiao X; Jaen JC; Cardozo MG; Liu J; Wang Z; Walker NP; Wesche H; Li S; Farrelly E; Xiao SH; Kayser F
Bioorg Med Chem Lett; 2008 Dec; 18(24):6352-6. PubMed ID: 18993068
[TBL] [Abstract][Full Text] [Related]
33. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
[TBL] [Abstract][Full Text] [Related]
34. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphlococcus aureus DNA polymerase III: design, synthesis, and biological evaluation.
Ali A; Taylor GE; Ellsworth K; Harris G; Painter R; Silver LL; Young K
J Med Chem; 2003 May; 46(10):1824-30. PubMed ID: 12723946
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B; Pan G; Corbett M; Li C; Kauffman GS; Pandit J; Robinson S; Wei L; Kozina E; Marr ES; Borzillo G; Knauth E; Barbacci-Tobin EG; Vincent P; Troutman M; Baker D; Rajamohan F; Kakar S; Clark T; Morris J
Bioorg Med Chem Lett; 2008 Jun; 18(11):3359-63. PubMed ID: 18456494
[TBL] [Abstract][Full Text] [Related]
38. Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.
Carraro F; Naldini A; Pucci A; Locatelli GA; Maga G; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Modugno M; Tintori C; Manetti F; Botta M
J Med Chem; 2006 Mar; 49(5):1549-61. PubMed ID: 16509573
[TBL] [Abstract][Full Text] [Related]
39. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR).
Hubbard RD; Bamaung NY; Palazzo F; Zhang Q; Kovar P; Osterling DJ; Hu X; Wilsbacher JL; Johnson EF; Bouska J; Wang J; Bell RL; Davidsen SK; Sheppard GS
Bioorg Med Chem Lett; 2007 Oct; 17(19):5406-9. PubMed ID: 17689078
[TBL] [Abstract][Full Text] [Related]
40. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
